It has also been demonstrated that the reduction in SKP2 by inhibiting menin, either genetically or pharmacologically, synergizes with iEGFRs to reduce CRC cell growth, increase CRC cell death, and reduce tumor xenograft growth more effectively than treatment with iEGFRs alone [253]. The gene discussed is SKP2; the disease is colorectal carcinoma.